JADE TEEN: Abrocitinib in adolescents with moderate-to-severe atopic dermatitis

Phase 3, randomised, double-blind trial of abrocitinib in atopic dermatitis (AD) (3 arms), sponsored by Pfizer. Primary endpoints: Investigator's Global Assessment Response of 'Clear' (0) or 'Almost Clear' (1) and >=2 Points Improvement at 12 weeks and Eczema Area and Severity Index Response >= 75% Improvement at 12 weeks. Started Feb 2019; status: completed.